IMAB
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- I-Mab completes enrollment in planned Phase 1b dose expansion study for Givastomig combined with immunochemotherapy in patients with first-line gastric cancersAug 11, 2025
- I-Mab presents positive Phase 1b dose escalation data for Givastomig combined with immunochemotherapy in first-line gastric cancer at ESMO GI 2025Jul 11, 2025
- I-Mab highlights positive Phase 1b dose escalation data for Givastomig combined with immunochemotherapy in first-line gastric cancer at ESMO GI 2025Jun 26, 2025